Abstract
The roles of calciotropic hormones in the pathogenesis and treatment of osteoporosis are not clearly understood. Here we have assessed serum levels of immunoreactive parathyroid hormone (PTH) and urinary cyclic AMP excretion before and after acute peroral phosphate administration in osteoporotic patients and normal subjects of the same age. In some osteoporotic patients serum levels of PTH were measured after prolonged (5 days) treatment with peroral phosphate. Serum levels of immunoreactive carboxyl-terminal flanking peptide (PDN-21) (katacalcin is a synonym) of the human calcitonin gene which are closely related to calcitonin levels were also measured before and after iv calcium injections (1). The diagnosis of osteoporosis was established on the basis of at least one vertebral compression fracture. Control subjects had normal serum levels of calcium, phosphate and creatinine, and they presented no history of renal, hepatic and intestinal disease. None of the subjects were treated with glucocorticoids or were alcoholics.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
J. Ittner, M. A. Dambacher, W. Born, J.-M. Ketelslegers, M. Buysschaert, P. M. Albert, A. E. Lambert, and J. A. Fischer, Diagnostic evaluation of measurements of carboxyl-terminal flanking peptide (PDN-21) of the human calcitonin gene in human serum, J. Clin. Endocrinol. Metab. 61: in press (1985).
C. Nagant de Deuxchaisnes, J. A. Fischer, M. A. Dambacher, J.-P. Devogelaer, C. E. Arber, J. M. Zanelli, J. A. Parsons, N. Loveridge, L. Bitensky, and J. Chayen, Dissociation of parathyroid hormone bio-activity and immunoreactivity in pseudohypoparathyroidism type I, J. Clin. Endocrinol.Metab. 53: 1105 (1981).
P. 011es, F. Tschopp, D. W. Dempster, P. H. Tobler, R. Muff, and J. A. Fischer, Potassium stimulates parathyroid hormone release in the absence of extracellular calcium. Mol. Cell. Endocrinol. 32: 1 (1983).
F. Albright, W. Bauer, D. Claflin, and J. R. Cokrill, Studies in parathyroid physiology. III. The effect of phosphate ingestion in clinical hyperparathroidism, J. Clin. Invest. 11: 411 (1932).
E. Reiss, J. M. Canterbury, M. A. Bercovitz, and E. L. Kaplan, The role of phosphate in the secretion of parathyroid hormone in man, J. Clin. Invest. 49: 2146 (1970).
U. Binswanger, and J. A. Fischer, Reponse of immunoreactive parathyroid hormone to intravenous phosphate infusion in primary hyperparathyroidism, Klin. Wschr. 52: 30 (1974).
J. C. Gallagher, B. L. Riggs, C. M. Jerpbak, and C. D. Arnaud, The effect of age on serum immunoreactive parathyroid hormone in normal and osteoporotic women, J. Lab. Clin. Med. 95: 373 (1980).
J. Reeve, P. J. Meunier, J. A. Parsons, M. Bernat, 0. L. M. Bijvoet, P. Coupron, C. Edouard, L. Klenerman, R. M. Neer, J. C. Renier, D. Slovik, F. J. F. E. Vismans, and J. T. Potts Jr., Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: A multicentre trial, Brit. Med. J. ii: 1340 (1980).
D. M. Slovik, R. M. Neer, and J. T. Potts Jr., Short-term effects of synthetic human parathyroid hormone-(1–34) administration on bone mineral metabolism in osteoporotic patients, J. Clin. Invest. 68: 1261 (1981).
H. Rasmussen, P. Bordier, L. Auquier, J. B. Eisinger, D. Kuntz, F. Caulin, B. Argemi, J. Gueris, and A. Julien, Effect of combined therapy with phosphate and calcitonin one bone volume in osteoporosis, Bone 2: 107 (1980).
C. Anderson, R. D. T. Cape, R. G. Crilly, A. B. Hodsman, and B. M. J. Wolfe, Preliminary observations of a form of coherence therapy for osteoporosis, Calc. Tissue Int. 36: 341 (1984).
P. H. Tobler, F. A. Tschopp, M. A. Dambacher, and J. A. Fischer, Salmon and human calcitonin-like peptides in man, Clin. Endocrinol. (Oxf.) 20: 253 (1984).
R. K. Craig, L. Hall, M. R. Edbrooke, J. Allison, and I. Maclntyre, Partial nucleotide sequence of human calcitonin precursor mRNA identifies flanking cryptic peptides, Nature (Lond.) 295: 345 (1982).
C. J. Hillyard, G. Abeyasekera, R. K. Craig, C. Myers, J. C. Stevenson, and I. Maclntyre, Katacalcin: A new plasma calcium-lowering hormone, Lancet i: 846 (1983).
B. A. Roos, M. B. Huber, R. S. Birnbaum, D. C. Aron, A. W. Lindall, K. Lips, and S. B. Baylin, Medullary thyroid carcinomas secrete a noncalcitonin peptide corresponding to the carboxyl-terminal region of preprocalcitonin, J. Clin. Endocrinol. Metab. 56: 802 (1983).
C. J. Hillyard, J. C. Stevenson, and I. Maclntyre, Relative deficiency of plasma-calcitonin in normal women, Lancet i: 961 (1978).
L. J. Deftos, M. H. Weisman, G. W. Williams, D. B. Karpf, A. M. Frumar, B. J. Davidson, J. G. Parthemore, and H. L. Judd, Influence of age and sex on plasma calcitonin in human beings, N. Engl. J. Med. 302: 1351 (1980).
J.-J. Body, and H. Heath III, Estimates of circulating monomeric calcitonin: Physiological studies in normal and thyroidectomized man, J. Clin. Endocrinol. Metab. 57: 897 (1983).
H. M. Taggart, J. L. Ivey, K. Sisom, C. H. Chesnut III, D. J. Baylink, M. B. Huber, and B. A. Roos, Deficient calcitonin response to calcium stimulation in postmenopausal osteoporosis?, Lancet i: 475 (1982).
R. D. Tiegs, J.-J. Body, H. W. Wahner, J. Barta, B. L. Riggs, and H. Heath III, Calcitonin secretion in postmenopausal osteoporosis, N. Engl. J. Med. 312: 1097 (1985).
R. Lindsay, D. M. Hart, J. M. Aitken, E. B. MacDonald, J. B. Anderson, and A. C. Clarke, Long-term prevention of postmenopausal osteoporosis by oestrogen: Evidence for an increased bone mass after delayed onset of oestrogen treatment, Lancet i: 1038 (1976).
L. S. Richelson, H. W. Wahner, L. J. Melton III, and B. L. Riggs, Relative contributions of aging and oestrogen deficiency to postmenopausal bone loss, N. Engl. J. Med. 311: 1273 (1984).
R. P. Heaney, J. C. Gallagher, C. C. Johnston, R. Neer, A. M. Parfitt, and G. D. Whedon, Calcium nutrition and bone health in the elderly, Am. J. Clin. Nutr. 36: 986 (1982).
J. F. Aloia, S. H. Cohn, J. A. Ostuni, R. Cane, and K. Ellis, Prevention of involutional bone loss by exercise, Ann. Intern. Med. 89: 356 (1978).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Plenum Press, New York
About this chapter
Cite this chapter
Dambacher, M.A., Ittner, J., Muff, R., Fischer, J.A. (1986). Parathyroid Hormone Secretory Responses to Peroral Phosphate and Stimulability of Serum Levels of Carboxyl-Terminal Flanking Peptide (PND-21) of the Human Calcitonin Gene by Calcium in Normal Subjects and Osteoporotic Patients. In: Massry, S.G., Olmer, M., Ritz, E. (eds) Phosphate and Mineral Homeostasis. Advances in Experimental Medicine and Biology, vol 208. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-5206-8_42
Download citation
DOI: https://doi.org/10.1007/978-1-4684-5206-8_42
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-5208-2
Online ISBN: 978-1-4684-5206-8
eBook Packages: Springer Book Archive